In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

Additionally, HIMS has minimal debt levels, with a debt-to-equity ratio below 1%, and holds $300 million in cash, representing a 42% cash-to-assets ratio. These figures underscore HIMS' financial ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Citi analyst Daniel Grosslight maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $140.00. The ...

While the Toronto Blue Jays are off today, they were staring down the barrel of a roster decision on Friday when Nathan Lukes ...

In a report released today, Daniel Grosslight from Citi maintained a Buy rating on McKesson (MCK – Research Report), with a price target of ...

Edwards Lifesciences Corp. EW is scheduled to report first-quarter 2025 results on April 23, after the market closes. In the ...